Review of consensus interferon in the treatment of chronic hepatitis C
Th Witthöft1University Hospital Schleswig Holstein Campus Lübeck, Dept of Medicine I, Division of Gastroenterology, Lübeck, Germany. 1Current address is the correspondence addressAbstract: Consensus interferon (CIFN) is an artificially engineered interferon tha...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5cd098d029a148ca966c30ef6b77c958 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5cd098d029a148ca966c30ef6b77c958 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5cd098d029a148ca966c30ef6b77c9582021-12-02T00:40:24ZReview of consensus interferon in the treatment of chronic hepatitis C1177-54751177-5491https://doaj.org/article/5cd098d029a148ca966c30ef6b77c9582008-09-01T00:00:00Zhttp://www.dovepress.com/review-of-consensus-interferon-in-the-treatment-of-chronic-hepatitis-c-a2317https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Th Witthöft1University Hospital Schleswig Holstein Campus Lübeck, Dept of Medicine I, Division of Gastroenterology, Lübeck, Germany. 1Current address is the correspondence addressAbstract: Consensus interferon (CIFN) is an artificially engineered interferon that reflects most of the human genotype 1 interferons and shows a higher biological and antiviral capacity in vitro. It has been used internationally to treat patients with chronic hepatitis C (HCV) infection before pegylated IFN became available. To mimic the half-life of PEG-IFN it has to be administered on a daily basis. The gold standard in the treatment of hepatitis C is well established and recommended. Today patients are being treated with a combination therapy of pegylated IFN and ribavirin. Length and dosage of therapy depends on the genotype of the virus. Patients with genotype 1 and 4 and high viral load should be treated for 48 weeks; for patients with these genotypes along with either low viral load or early virological response, therapy for 24 weeks is sufficient. Patients with genotype 2 and 3 should be treated for up to 24 weeks. However, daily dosing of IFN-α, eg, CIFN, resulting in a higher cumulative dosage, might be beneficial and more efficacious in some chronic HCV-infected patients. Patients with genotype 1, having initially high viral load (>800,000 IU/mL) and showing advanced liver disease with progressive fibrosis or even cirrhosis comprise the difficult-to-treat in order to overcome the infection. This review summarizes and critically discusses the published data on the treatment of HCV with CIFN.Keywords: CIFN, interferon-alfacon-1, early virological response, sustained virological response, PCR, pegylated IFN-α-2a/b Th WitthöftDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 4, Pp 635-643 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Th Witthöft Review of consensus interferon in the treatment of chronic hepatitis C |
| description |
Th Witthöft1University Hospital Schleswig Holstein Campus Lübeck, Dept of Medicine I, Division of Gastroenterology, Lübeck, Germany. 1Current address is the correspondence addressAbstract: Consensus interferon (CIFN) is an artificially engineered interferon that reflects most of the human genotype 1 interferons and shows a higher biological and antiviral capacity in vitro. It has been used internationally to treat patients with chronic hepatitis C (HCV) infection before pegylated IFN became available. To mimic the half-life of PEG-IFN it has to be administered on a daily basis. The gold standard in the treatment of hepatitis C is well established and recommended. Today patients are being treated with a combination therapy of pegylated IFN and ribavirin. Length and dosage of therapy depends on the genotype of the virus. Patients with genotype 1 and 4 and high viral load should be treated for 48 weeks; for patients with these genotypes along with either low viral load or early virological response, therapy for 24 weeks is sufficient. Patients with genotype 2 and 3 should be treated for up to 24 weeks. However, daily dosing of IFN-α, eg, CIFN, resulting in a higher cumulative dosage, might be beneficial and more efficacious in some chronic HCV-infected patients. Patients with genotype 1, having initially high viral load (>800,000 IU/mL) and showing advanced liver disease with progressive fibrosis or even cirrhosis comprise the difficult-to-treat in order to overcome the infection. This review summarizes and critically discusses the published data on the treatment of HCV with CIFN.Keywords: CIFN, interferon-alfacon-1, early virological response, sustained virological response, PCR, pegylated IFN-α-2a/b |
| format |
article |
| author |
Th Witthöft |
| author_facet |
Th Witthöft |
| author_sort |
Th Witthöft |
| title |
Review of consensus interferon in the treatment of chronic hepatitis C |
| title_short |
Review of consensus interferon in the treatment of chronic hepatitis C |
| title_full |
Review of consensus interferon in the treatment of chronic hepatitis C |
| title_fullStr |
Review of consensus interferon in the treatment of chronic hepatitis C |
| title_full_unstemmed |
Review of consensus interferon in the treatment of chronic hepatitis C |
| title_sort |
review of consensus interferon in the treatment of chronic hepatitis c |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/5cd098d029a148ca966c30ef6b77c958 |
| work_keys_str_mv |
AT thwitthampoumlft reviewofconsensusinterferoninthetreatmentofchronichepatitisc |
| _version_ |
1718403557287264256 |